Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J, Just, S, Danebod, K, Munk, H, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Biosimilar-to-Biosimilar Switching in Routine Care-Results on > 1,600 Patients with Inflammatory Arthritis in the DANBIO Registry ', Arthritis & Rheumatology, vol. 74, no. Suppl. 9, 1112, pp. 2209-2211 .
Nabi, H, Georgiadis, S, Loft, A G, Hendricks, O, Jensen, D V, Andersen, M, Chrysidis, S, Colic, A, Danebod, K, Hussein, M R, Kalisz, M H, Kristensen, S, Lomborg, N, Manilo, N, Munk, H L, Pedersen, J K, Raun, J L, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2021, ' Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab : Nationwide observational study emulating a randomised clinical trial ', Annals of the Rheumatic Diseases, vol. 80, no. 11, pp. 1400-1409 . https://doi.org/10.1136/annrheumdis-2021-219951 Nabi, H, Georgiadis, S, Loft, A G, Hendricks, O, Jensen, D V, Andersen, M, Chrysidis, S, Colic, A, Danebod, K, Hussein, M R, Kalisz, M H, Kristensen, S, Lomborg, N, Manilo, N, Munk, H L, Pedersen, J K, Raun, J L, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2021, ' Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab : Nationwide observational study emulating a randomised clinical trial ', Annals of the rheumatic diseases, vol. 80, no. 11, pp. 1400-1409 . https://doi.org/10.1136/annrheumdis-2021-219951
Nabi, H, Glintborg, B, Loft, A G, Hendricks, O, Pedersen, J K, Just, S A, Ahmed, R, Danebod, K, Munk, H, Colic, A, Linauskas, A, Jensen, D V, Raun, J, Grydehøj, J, Christensen, L B, Manilo, N, Lomborg, N, Kristensen, S, Mehnert, F, Krogh, N S & Hetland, M 2021, ' Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111 ', ACR Convergence 2021, 03/11/2021-09/11/2021 pp. 1161-1163 . < https://acrabstracts.org/abstract/biosimilar-to-biosimilar-infliximab-switching-in-real-world-patients-with-inflammatory-arthritis-followed-in-the-danish-danbio-registry-switch-from-originator-infliximab-to-ct-p13-and-then-to-gp1111/ >